top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.74 -0.58 (-3.00%)
Delayed Quote Updated: 2:31 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
From Legend Biotech Corporation
Via Business Wire
News headline image
Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug ↗
Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,  
Via Benzinga
News headline image
Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast ↗
 
Via Benzinga
News headline image
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
News headline image
3 Biotech Stocks That Analysts Are Drooling Over ↗
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
News headline image
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
From Legend Biotech Corporation
Via Business Wire
News headline image
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
News headline image
Expert Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
Analyst's Verdict on Legend Biotech: Doubts On Commercial Execution, Long- Term Market Share ↗
 
Via Benzinga
News headline image
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
News headline image
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
From Legend Biotech
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023 ↗
 
Via Benzinga
News headline image
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗
 
Via Benzinga
News headline image
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech Announces Participation in Upcoming Investor Conference
From Legend Biotech Corporation
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
From Legend Biotech Corporation
Via Business Wire
News headline image
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
News headline image
After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech? ↗
Legend's cell therapy seems like it's a winner, but it might be priced in already. 
Via The Motley Fool
News headline image
Potential Breakout Setups To Watch On Wednesday ↗
The U.S. stock market has weakened throughout Tuesday’s trading session and the major indices were sitting near session lows heading into the closing bell. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page